Phase III HARMONY trial conducted by Acadia Pharmaceuticals ( ACAD ) recently delivered robust statistically superior data (p=0.0033) compared to placebo in time to relapse of dementia-related psychosis (DRP), explains biotech specialist John McCamant , editor of The Medical Te...

— Pimavanserin as adjunctive treatment to SSRI/SNRI therapies significantly improved sexual dysfunction symptoms compared to placebo in MDD patients ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that based on secondary analyses from its Phase 2 CLARITY study, adju...

Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin (NASDAQ: AMRN) and Exelixis (NASDAQ: EXEL) check the boxes for what investors should look for in a promising biotech company: compelling drugs, increasing sales, near-term catalysts, and the possibility of being acquired. Like Goldilocks ...